From the bench to the bedside: emerging new treatments in multiple myeloma

RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple …

K Mashimo, M Tsubaki, T Takeda, R Asano… - Clinical and …, 2019 - Springer
The survival and growth of multiple myeloma (MM) cells are facilitated by cell–cell
interactions with bone marrow stromal cells and the bone marrow microenvironment. These …
被引用次数：15 相关文章 所有 6 个版本